13% reported weight loss · 5.4% loss with placebo · 76 weeks
Up to 6.0 mg once weekly
Adults with obesity or overweight and a weight-related complication; without diabetes
Trial calls this the treatment-regimen estimand; includes discontinuation and prohibited obesity therapies. Modified intention-to-treat population: 725 dosed of 726 randomized. Investigational; phase 3 results reported
Safety context
Gastrointestinal events predominate; full safety details require the trial report.
Limitations: Cross-trial comparison is indirect. Trial population and estimand differ from efficacy headlines.
Investigational; no approved trade name identified as of 2026-09-13. Survodutide and BI 456906 are not approved brands; obesity and MASH are distinct development programs.
Boehringer Ingelheim · Global licensee solely responsible for development and commercialization.; Zealand Pharma · Licensor and research partner; eligible for milestones and royalties under the collaboration.
Uses, doses and availability depend on the formulation, indication and country. Study doses below describe research; they are not prescribing instructions.
The molecule
Activates GLP-1 and glucagon receptors.
Structure not yet verified
Structure not verified
Activates GLP-1 and glucagon receptors.
Shown: Peptide drug
The downloaded PubChem biological diagram contains stereochemical and unexpanded modification annotations that were not reconciled with the exact drug, so it was withheld.
A next milestone is not summarized for this therapy. This does not mean development has ended.
Development history3 selected milestones
Survodutide · compound history across indications
Selected milestones only. Earlier studies may be missing; the first listed date should not be interpreted as the start of development.
Boehringer–Zealand partnership
Zealand entered a licence, research and development collaboration granting Boehringer global rights to the lead dual glucagon/GLP-1 program, now survodutide.